Actively Recruiting

Phase Not Applicable
Age: 22Years - 64Years
All Genders
ID06599099

Building Mood State Classifiers to Inform Deep Brain Stimulation of Treatment-Resistant Bipolar Depression

Led by Wayne Goodman MD · Updated on 2026-01-26

10

Participants Needed

4

Research Sites

52 weeks

Total Duration

On this page

Sponsors

W

Wayne Goodman MD

Lead Sponsor

U

University of Washington

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating the use of Deep Brain Stimulation (DBS) in people with severe treatment-resistant bipolar depression (TRBD). This study is conducted only at Baylor College of Medicine and aims to improve DBS targeting to better manage symptoms of TRBD by surgically implanting electrodes in specific brain areas. DBS delivers electrical currents to influence brain circuits involved in bipolar depression, but participants should understand that this is experimental and may not provide direct benefit. Risks include brain bleeding, infection, seizures, and other potential complications. Participants will undergo a detailed screening process including medical, psychiatric, and cognitive evaluations before surgery. The study involves implanting a Medtronic Percept RC DBS system with bilateral leads targeting specific brain regions. After surgery, the device will be activated and programmed over several visits. The study includes a blinded discontinuation period at 12 months to assess ongoing DBS effects. Participants will stay locally during several 24-hour monitoring periods in the NeuroBehavioral Unit to collect neural and behavioral data, using wearable sensors and mobile apps. Throughout the 20-month study, participants will attend about 23 visits for clinical assessments, questionnaires, neuropsychological and behavioral testing, and device programming. Data collection includes brain imaging, mood and mania rating scales, side effect monitoring, and continuous behavioral and neural recordings. Safety and symptom changes will be closely tracked using standardized tools like the Montgomery-Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS). The study aims to better understand DBS effects and improve treatment for TRBD.

CONDITIONS

Brief Title

Deep Brain Stimulation of Treatment-Resistant Bipolar Depression

Who Can Participate

Age: 22Years - 64Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females aged 22 to 64, inclusive
  • Diagnosis of Bipolar I disorder currently in a major depressive episode confirmed by SCID-5
  • Montgomery-Asberg Depression Rating Scale (MADRS) score of 27 or higher at screening and baseline
  • Clinical Global Impressions Scale (CGI-S) greater than 4 and Young Mania Rating Scale (YMRS) less than 12 at screening and baseline
  • History of failure to respond or maintain response to at least four evidence-based bipolar depression treatments, including two FDA-approved medications or electroconvulsive therapy
  • Currently taking at least one evidence-based medication for bipolar disorder or unable to tolerate such medications
  • Initial mood episode occurred before age 40
  • Stable dose of psychotropic medications for at least four weeks prior to surgery
  • Minimum score on the Montreal Cognitive Assessment (MoCA)
  • Able and willing to give informed consent and sign a treatment contract including identification of a reliable informant
Not Eligible

You will not qualify if you...

  • Lifetime history of psychotic disorder or psychotic symptoms outside bipolar mood episodes
  • Currently in a manic or hypomanic episode or experiencing rapid cycling (4 or more mood episodes in past 12 months)
  • Primary psychiatric disorder other than bipolar disorder treated in past 12 months
  • Moderate or severe alcohol or substance use disorder in past 12 months (excluding nicotine)
  • Intellectual disability or neurocognitive disorder
  • Major unstable medical conditions such as liver, kidney, cardiovascular issues, infections, cancer, or major neurological disorders
  • Medical contraindication to surgery or poor surgical candidate
  • Pregnant, breastfeeding, or planning pregnancy within 24 months
  • Contraindications for MRI
  • Clinically significant personality disorder impacting safety or psychiatric status
  • Serious risk of suicide making outpatient participation unsuitable
  • Participation in another investigational clinical trial within past 30 days
  • Current implanted stimulation devices like pacemakers or neurostimulators
  • No regular contact with at least one adult or undomiciled
  • Body mass index (BMI) less than 16 or greater than 40 kg/m2
  • Need for diathermy treatment
  • Unable to sign informed consent
  • Not under psychiatric care at screening and throughout study duration

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

2 visits (screening and baseline visits spaced over approximately 1 month)

Surgery

Duration - 1 day

Participants undergo implantation of bilateral deep brain stimulation leads targeting specific brain regions using a robotic surgical workflow with intraoperative behavioral testing to determine optimal lead placement.

1 surgical visit (in-person)

Treatment

Duration - Approximately 12 months

Participants receive device activation and ongoing deep brain stimulation programming with frequent visits for assessment and optimization, including multiple stays in a NeuroBehavioral Unit for high-density neural and behavioral monitoring.

Weekly visits for the first 8 weeks, then monthly visits through month 12; 8 total 24-hour NeuroBehavioral Unit stays

One Month Blinded Discontinuation Period

Duration - 1 month

Participants undergo a one month blinded discontinuation where the deep brain stimulation device is turned off gradually to assess dependence on ongoing stimulation.

Visits during gradual taper period with clinical evaluations

Follow-up

Duration - Up to 8 months

Participants are monitored with monthly clinical evaluations to assess efficacy and safety after the discontinuation period, with decisions made about restarting or deactivating the device.

Monthly visits through month 20, including final study visit at month 20

Trial Site Locations

Total: 4 locations

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Active, Not Recruiting

2

Baylor College of Medicine

Houston, Texas, United States, 77030

Actively Recruiting

3

Rice University

Houston, Texas, United States, 77030

Active, Not Recruiting

4

University of Washington

Seattle, Washington, United States, 98195

Active, Not Recruiting

Loading map...

Research Team

M

Michelle Avendano

L

Luke Jumper

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase 3, Randomized, Double-blind, Placebo-Controlled Stud...

Bipolar Disorder

Actively Recruiting

28 locations

Adjunctive Behavioural Activation for Bipolar Depression: A ...

Bipolar Depression

Actively Recruiting

1 location

Low-Dose Adjunctive Brexpiprazole in the Treatment of Bipola...

Bipolar Depression

Actively Recruiting

3 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here